Evidence map›Paper›PMID 39436414›Full record

ArticleJournal of cancer research and clinical oncology2024

Explainable

Yan Zuo, Qiufang Liu, Nan Li, Panli Li, Yichong Fang, Linjie Bian, Jianping Zhang, Shaoli Song

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. The predictive value ofFrontiers in medicine · 2026
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yan Zuo *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Qiufang Liu *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Nan LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Panli LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Yichong FangCollege of Chemistry and Materials Science, Shanghai Normal University, Shanghai, 200233, P. R. China.
Linjie BianDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Jianping ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, P. R. China. shaoli-song@163.com.ORCID http://orcid.org/0000-0003-2544-7522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo establish an explainable

methodsBaseline

resultsSex and SUV

conclusionThe explainable EGFR mutation status prediction model have certain clinical practicability and good generalization performance, which may help in the timely selection of treatment options and prognosis prediction in patients with LUAD.

Indexed as

Adenocarcinoma of LungErbB ReceptorsFluorodeoxyglucose F18Lung NeoplasmsMutationPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRadiomicsRadiopharmaceuticalsEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18RadiopharmaceuticalsEpidermal growth factor receptorExplainable machine learningLung adenocarcinomaPET/CTRadiomics

Identifiers

PMID39436414
PMCPMC11496337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.